Hot Investor Mandate: Impact VC Seeks All Life Science Companies that Target CNS Diseases, Investing Up to $8M Per Deal

An impact venture capital firm dedicated to funding private, early-stage whose innovation(s) significantly help or cure patients suffering from psychiatric and/or neurological diseases. The firm will invest in Seed and Series A rounds, typically allocating $200k – 8 million USD for each deal. The firm looks for deals globally and plans to make several investments in the upcoming year immediately following the first close of the fund. The firm is willing to lead rounds or co-invest as long as the investment falls within their investment criteria.

The firm is interested in devices, digital health, therapeutics, and diagnostics companies that focus on improving the treatment or curing diseases of the central nervous system. The firm prefers technologies and therapeutics that are disease modifying and/or gain significant traction in disease symptom reduction. Technologies that improve quality of life or treatment delivery in neurological and psychiatric patient populations will also be considered.

The firm sometimes prefers to take a board seat in companies in which they invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.